Fibrinolytic treatment in suspected acute myocardial infarction - Use and risks in clinical practice

European Journal of Clinical Pharmacology

Volumn 52, Issue 3, 1997, Pages 179-182

  Beermann, B ^a   Von Bahr, C ^a   Sundstrom A ^a  

^a MEDICAL PRODUCTS AGENCY   (Sweden)

Author keywords

Alteplase; Attire myocardial infarction; Clinical practice; Fibrinolysis; streptokinase

Indexed keywords

ALTEPLASE; FIBRINOLYTIC AGENT; STREPTOKINASE;

ADULT; AGED; ARTICLE; CLINICAL PRACTICE; CORONARY CARE UNIT; DISEASE SEVERITY; DOSE RESPONSE; ELECTROCARDIOGRAM; FEMALE; FIBRINOLYSIS; HEART BUNDLE BRANCH BLOCK; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; ST SEGMENT ELEVATION;

ACUTE DISEASE; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PHYSICIAN'S PRACTICE PATTERNS; PROSPECTIVE STUDIES; STREPTOKINASE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0030919937     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050271     Document Type: Article

References (18)

1. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group (1994) Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 343: 311-322
2. Pharmacological Treatment of Arterial Thromboembolism (1987) National Board of Health and Welfare, Drug Information Committee 3
3. Trombolytisk behandling vid hjärtinfark (1988) Information från Socialstyrelsens läkemedelsavdelning 6: 195-195
4. Wallentin Lars (1990) Trombolys vid hjärtinfarkt och behandling av instabil kranskärlssjukdom. SOS Rapport 12
5. Snabb trombolys vid akut hjärtinfarkt (1994) Läkartidningen 91: 1098-1101
6. Beermann B (1994) Trombolysbehandling vid hjärtinfarkt. Läkartidningen 91: 1059-1061
7. Ketley D, Woods KL (1993) Impact of clinical trials on clinical practice: example of thrombolysis for acute myocardial infarction. Lancet 342: 891-894
8. European Secondary Prevention Study Group (1996) Translation of clinical trials into practice: A European population based study of the use of thrombolysis for acute myocardial infarction. Lancet 347: 1203-1207
9. French JK, Williams BF, Hart HH, Wyatt S, Poole JE, Ingram C, Ellis CJ, Williams MG, White HD (1996) Prospective evaluation of eligibility for thrombolytic therapy in acute myaocardial infarction. BMJ 312: 1637-1641
10. Wilkinson P, Laji K, Ranjadayalan L, Parsons, Timmis AD (1994) Acute myocardial infarction in women: survival analysis in first six months. BMJ 309: 566-569
11. Ketley D, Woods KL (1995) Selection factors for the use of thrombolytic treatment in acute myocardial infarction: a population based study of current practice in the United Kingdom. Br Heart J 74: 224-228
12. Gurwitz JH, Gore JM, Goldberg RJ, Rubison M, Chandra N, Rogers WJ (1996) Recent age-related trends in the use of thrombolytic therapy in patients who have had acute myocardial infarction. Ann Intern Med 124: 283-288
13. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI) (1986) Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet i: 397-401
14. The GUSTO Investigators (1993) An international trial comparing four thrombolytic strategies for acute myocardial infarction. New Engl J Med 329: 673-682
15. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (1990) GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12 490 patients with acute myocardial infarction. Lancet 336: 65-71
16. First International Study of Infarct Survival Collaborative Group (1986) Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction:ISIS-1.Lancet ii: 57-66
17. Brand DA, Newcomer LN, Freiburger A, Tian H (1995) Cardiologists' Practices Compared With Practice Guidelines: Use of Beta-Blockade after Acute Myocardial Infarction. JACC 26: 1432-1436
18. Apoteksbolaget (1996) Svensk Läkemedelsstatistik 95